Shares of Novavax (NVAX, Financial), a biotechnology firm specializing in vaccine development, experienced a significant drop of 5.11%. The stock is currently priced at $12.92 with a trading volume of approximately 3.03 million shares, reflecting a turnover rate of 1.89% and a price fluctuation of 6.10%.
Recent financial data reveals Novavax achieved a revenue of $415 million, net earnings of $162 million, and earnings per share of $1.09. The company's gross profit stands at $379 million, with a price-to-earnings ratio of -4.94.
When it comes to analyst recommendations, 40% suggest buying the stock, 40% recommend holding, and 20% advise selling out of the five institutions that provided ratings.
Within the biotechnology sector, which saw a minor decrease of 0.06%, other companies showed varied performances. Notable gainers include Scholar Rock Holding Corporation, which had a turnover rate of 1649.72%, and Reviva Pharmaceuticals Holdings Inc, with significant price movements.
Novavax, in collaboration with its Swedish subsidiary, is in the clinical development phase, focusing on vaccines for both known and emerging diseases. The company’s vaccine technology is envisioned to have broad applications across various infectious diseases.
